Medical Treatment Options for Ulcerative Colitis

 

 Buy Article Permissions and Reprints

Abstract

The landscape of management of ulcerative colitis, a type of inflammatory bowel disease, continues to change with advancement in pharmaceutical options as well as clinical treatment targets. Ulcerative colitis primarily involves the superficial layers of the large bowel, and cause active inflammation that can affect the colon from the rectum to the cecum in a relapsing and a remitting course. In this review, we provide evidence-based guidance on the selection of appropriate medical therapies based on individual patient and disease characteristics, with a focus on biologics and small molecules. We also review the role of surgery and management of acute severe ulcerative colitis.

Publication History

Article published online:
09 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Shivashankar R, Tremaine WJ, Harmsen WS, Loftus Jr EV. Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 2017; 15 (06) 857-863
  CrossrefPubMedGoogle Scholar
• 2 Safroneeva E, Vavricka S, Fournier N. et al; Swiss IBD Cohort Study Group. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Aliment Pharmacol Ther 2015; 42 (05) 540-548
  CrossrefPubMedGoogle Scholar
• 3 Turner D, Ricciuto A, Lewis A. et al; International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160 (05) 1570-1583
  CrossrefPubMedGoogle Scholar
• 4 Sands BE, Peyrin-Biroulet L, Loftus Jr EV. et al; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381 (13) 1215-1226
  CrossrefPubMedGoogle Scholar
• 5 Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017; 152 (02) 362-373.e3
  CrossrefPubMedGoogle Scholar
• 6 Peyrin-Biroulet L, Sandborn W, Sands BE. et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (09) 1324-1338
  CrossrefPubMedGoogle Scholar
• 7 Peyrin-Biroulet L, Panés J, Sandborn WJ. et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016; 14 (03) 348-354.e17
  CrossrefPubMedGoogle Scholar
• 8 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114 (03) 384-413
  CrossrefPubMedGoogle Scholar
• 9 Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology 2015; 149 (01) 238-245
  CrossrefPubMedGoogle Scholar
• 10 Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs 2015; 75 (08) 879-886
  CrossrefPubMedGoogle Scholar
• 11 Mahadevan U, Long MD, Kane SV. et al; Crohn's Colitis Foundation Clinical Research Alliance. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 2021; 160 (04) 1131-1139
  Google Scholar
• 12 Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30 (02) 126-137
  CrossrefPubMedGoogle Scholar
• 13 Walker GJ, Harrison JW, Heap GA. et al; IBD Pharmacogenetics Study Group. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA 2019; 321 (08) 773-785
  CrossrefPubMedGoogle Scholar
• 14 Dubinsky MC, Lamothe S, Yang HY. et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118 (04) 705-713
  CrossrefPubMedGoogle Scholar
• 15 Beaugerie L. Lymphoma: the bête noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 2013; 145 (05) 927-930
  CrossrefPubMedGoogle Scholar
• 16 Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut 2014; 63 (12) 1843-1853
  CrossrefPubMedGoogle Scholar
• 17 Bourrier A, Carrat F, Colombel JF. et al; CESAME study group. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther 2016; 43 (02) 252-261
  CrossrefPubMedGoogle Scholar
• 18 Sandborn WJ, Feagan BG, Marano C. et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146 (01) 85-95 , quiz e14–e15
  CrossrefPubMedGoogle Scholar
• 19 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142 (02) 257-65.e1 , 3
  CrossrefPubMedGoogle Scholar
• 20 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23) 2462-2476
  CrossrefPubMedGoogle Scholar
• 21 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015; 11: 63-73
  PubMedGoogle Scholar
• 22 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146 (02) 392-400.e3
  CrossrefPubMedGoogle Scholar
• 23 Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20 (10) 1862-1869
  CrossrefPubMedGoogle Scholar
• 24 Nielsen OH, Loftus Jr EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11: 174
  CrossrefPubMedGoogle Scholar
• 25 Hindryckx P, Vande Casteele N, Novak G. et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients?. J Crohn's Colitis 2018; 12 (01) 105-119
  CrossrefPubMedGoogle Scholar
• 26 Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106 (12) 2146-2153
  CrossrefPubMedGoogle Scholar
• 27 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7 (08) 874-881
  CrossrefPubMedGoogle Scholar
• 28 DʼHaens G, Reinisch W, Panaccione R. et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid registry. Am J Gastroenterol 2018; 113 (06) 872-882
  CrossrefPubMedGoogle Scholar
• 29 Nyboe Andersen N, Pasternak B, Basit S. et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014; 311 (23) 2406-2413
  CrossrefPubMedGoogle Scholar
• 30 Sazonovs A, Kennedy NA, Moutsianas L. et al; PANTS Consortium. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology 2020; 158 (01) 189-199
  CrossrefPubMedGoogle Scholar
• 31 Kennedy NA, Heap GA, Green HD. et al; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4 (05) 341-353
  CrossrefPubMedGoogle Scholar
• 32 Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10 (10) 1079-1087 , quiz e85–e86
  CrossrefPubMedGoogle Scholar
• 33 Ben-Horin S, Waterman M, Kopylov U. et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11 (04) 444-447
  CrossrefPubMedGoogle Scholar
• 34 Yarur AJ, Kubiliun MJ, Czul F. et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13 (06) 1118-24.e3
  CrossrefPubMedGoogle Scholar
• 35 Colombel JF, Sands BE, Rutgeerts P. et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66 (05) 839-851
  CrossrefPubMedGoogle Scholar
• 36 Feagan BG, Rutgeerts P, Sands BE. et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369 (08) 699-710
  CrossrefPubMedGoogle Scholar
• 37 Hu A, Kotze PG, Burgevin A. et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol 2021; 19 (07) 1366-1376.e2
  CrossrefPubMedGoogle Scholar
• 38 Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019; 58 (Suppl. 01) i43-i54
  CrossrefPubMedGoogle Scholar
• 39 Ytterberg SR, Bhatt DL, Mikuls TR. et al; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386 (04) 316-326
  CrossrefPubMedGoogle Scholar
• 40 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47 (02) 162-175
  CrossrefPubMedGoogle Scholar
• 41 Sandborn WJ, Su C, Sands BE. et al; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376 (18) 1723-1736
  CrossrefPubMedGoogle Scholar
• 42 Honap S, Chee D, Chapman TP. et al; LEO [London, Exeter, Oxford] IBD Research Consortium. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohn's Colitis 2020; 14 (10) 1385-1393
  CrossrefPubMedGoogle Scholar
• 43 Vermeire S, Su C, Lawendy N. et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohn's Colitis 2021; 15 (07) 1130-1141
  CrossrefPubMedGoogle Scholar
• 44 Sandborn WJ, Ghosh S, Panes J. et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020; 158 (08) 2139-2149.e14
  CrossrefPubMedGoogle Scholar
• 45 Vermeire S, Danese S, Zhou W. et al. OP23 efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study. J Crohn's Colitis 2021; 15 (Suppl. 01) S021-S022
  CrossrefPubMedGoogle Scholar
• 46 Sands BE, Sandborn WJ, Panaccione R. et al; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381 (13) 1201-1214
  CrossrefPubMedGoogle Scholar
• 47 Sandborn WJ, Feagan BG, D'Haens G. et al; True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2021; 385 (14) 1280-1291
  CrossrefPubMedGoogle Scholar
• 48 Edwards FCTS, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4: 299-315
  CrossrefPubMedGoogle Scholar
• 49 Dinesen LWalsh AJ, Protic MN. et al. The pattern and outcome of acute severe coliti. J Crohn's Colitis 2010; 4 (04) 431-437
  CrossrefPubMedGoogle Scholar
• 50 Truelove SCWL. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2 (4884): 375-378
  CrossrefPubMedGoogle Scholar
• 51 Feuerstein JDIK, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020; 158 (05) 1450-1461
  CrossrefPubMedGoogle Scholar
• 52 Järnerot G, Hertervig E, Friis-Liby I. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128 (07) 1805-1811
  CrossrefPubMedGoogle Scholar
• 53 Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94 (06) 1587-1592 . Doi: 10.1016/S0002-9270(99)00205-1
  CrossrefPubMedGoogle Scholar
• 54 Christensen B, Gibson PR, Micic D. et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 2019; 17 (03) 486-493
  CrossrefPubMedGoogle Scholar
• 55 Berinstein JA, Sheehan JL, Dias M. et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol 2021; 19 (10) 2112-2120.e1
  CrossrefPubMedGoogle Scholar
• 56 Cacheux W, Seksik P, Lemann M. et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103 (03) 637-642
  CrossrefPubMedGoogle Scholar
• 57 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?. Clin Gastroenterol Hepatol 2015; 13 (02) 336-338
  CrossrefPubMedGoogle Scholar
• 58 Travis SPFJ, Farrant JM, Ricketts C. et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38 (06) 905-910
  CrossrefPubMedGoogle Scholar
• 59 Moore AC, Bressler B. Acute severe ulcerative colitis: the Oxford criteria no longer predict in-hospital colectomy rates. Dig Dis Sci 2020; 65 (02) 576-580
  CrossrefPubMedGoogle Scholar
• 60 Ho GTMC, Mowat C, Goddard CJ. et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19 (10) 1079-1087
  CrossrefPubMedGoogle Scholar